In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
The company is confident of addressing all the observations within the stipulated time
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
